Karyopharm Therapeutics (KPTI) Long-Term Investments (2014 - 2021)

Karyopharm Therapeutics (KPTI) has 8 years of Long-Term Investments data on file, last reported at $2.0 million in Q3 2021.

• Quarterly Long-Term Investments fell 94.91% year-over-year to $2.0 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $2.0 million (down 94.91% YoY) and the FY2020 annual result came in at $24.2 million, up 1101.14% from the prior year.
• Long-Term Investments was little changed at $2.0 million in Q3 2021, from $2.0 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $48.9 million in Q2 2020 to a low of $2.0 million in Q4 2018.
• A 5-year average of $19.5 million and a median of $10.3 million in 2018 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2020 — Long-Term Investments soared 1847.13% — and 2021, when it tumbled 95.89%.
• Tracing KPTI's Long-Term Investments over 5 years: stood at $29.4 million in 2017, then sank by 93.19% to $2.0 million in 2018, then advanced by 0.75% to $2.0 million in 2019, then soared by 1101.14% to $24.2 million in 2020, then slumped by 91.72% to $2.0 million in 2021.
• The last three Long-Term Investments figures came in at $2.0 million (Q3 2021), $2.0 million (Q2 2021), and $7.7 million (Q1 2021), per Business Quant data.